Ezetimibe: New perspectives in lipid lowering treatment
P Jankowski, M Loster… - Cardiology Journal, 2007 - journals.viamedica.pl
Therapeutic goals for lipid lowering treatment in the prevention of ischemic heart disease
are often not reached in clinical practice. Even the highest doses of statins do not guarantee …
are often not reached in clinical practice. Even the highest doses of statins do not guarantee …
[PDF][PDF] Ezetimibe-a new approach in hypercholesterolemia management
MS Kostapanos, MS Elisaf, DP Mikhailidis - Pharmacol Rep, 2012 - Citeseer
Suchy et al.[10] discuss the benefits of ezetimibe beyond lipid-lowering as well as its effects
on atherosclerosis. Some comments may be of interest. Reducing low density lipoprotein …
on atherosclerosis. Some comments may be of interest. Reducing low density lipoprotein …
Eesti südame-ja veresoonkonnahaiguste preventsiooni juhend
M Viigimaa, J Eha, A Hedman, P Kampus, A Liiver… - Eesti Arst, 2006 - ojs.utlib.ee
Eesti südame-ja veresoonkonnahaiguste preventsiooni juhend põhineb Euroopa
Kardioloogide Seltsi südame-ja veresoonkonnahaiguste ennetamise juhistel (1) ning …
Kardioloogide Seltsi südame-ja veresoonkonnahaiguste ennetamise juhistel (1) ning …
[HTML][HTML] Двойное ингибирование холестерина-новый подход к эффективному контролю гиперлипидемии и атеросклероза
АВ Сусеков, НБ Горнякова, МЮ Зубарева… - Кардиоваскулярная …, 2009 - cyberleninka.ru
Повышение уровня холестерина липопротеринов низкой плотности (ХС ЛНП) один из
основных факторов риска (ФР) ишемической болезни сердца и атеросклероза …
основных факторов риска (ФР) ишемической болезни сердца и атеросклероза …
Ezetimibe effectively lowers LDL‐cholesterol in cardiac allograft recipients on stable statin therapy
MH Konstandin, E Blessing, A Doesch… - Clinical …, 2008 - Wiley Online Library
We investigated tolerability and efficacy of ezetimibe treatment (10 mg/d) in 25 heart allograft
recipients already on stable statin therapy. Total cholesterol (TC), low‐density cholesterol …
recipients already on stable statin therapy. Total cholesterol (TC), low‐density cholesterol …
强化调脂治疗的安全性
黄震华 - 中国新药与临床杂志, 2010 - cqvip.com
强化调脂治疗的安全性-[维普官方网站]-www.cqvip.com-维普网 我的维普 购物车 充值 客服 首页
| 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术机构 您的位置 …
| 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术机构 您的位置 …
[HTML][HTML] The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
CM Ballantyne, AL Catapano - European Atherosclerosis Journal, 2022 - eathj.org
The causal role of low-density lipoprotein cholesterol LDL-C in atherosclerotic-related
cardiovascular disease (ASCVD) has been undoubtedly established over the last decades …
cardiovascular disease (ASCVD) has been undoubtedly established over the last decades …
Meta‐analysis methods and models with applications in evaluation of cholesterol‐lowering drugs
In this paper, we propose a class of multivariate random effects models allowing for the
inclusion of study‐level covariates to carry out meta‐analyses. As existing algorithms for …
inclusion of study‐level covariates to carry out meta‐analyses. As existing algorithms for …
[HTML][HTML] Перспективы применения эзетимиба в кардиологической практике
АА Лякишев, АЕ Семенова… - Атеросклероз и …, 2010 - cyberleninka.ru
В патогенезе атеросклероза большая роль отводится холестериновой гипотезе
прогрессирования заболевания. Показано, что повышенный уровень холестерина …
прогрессирования заболевания. Показано, что повышенный уровень холестерина …